105 related articles for article (PubMed ID: 16888145)
1. Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38.
Arimura A; Li M; Batuman V
Ann N Y Acad Sci; 2006 Jul; 1070():1-4. PubMed ID: 16888145
[TBL] [Abstract][Full Text] [Related]
2. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
[TBL] [Abstract][Full Text] [Related]
3. Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study.
Li M; Maderdrut JL; Lertora JJ; Batuman V
Peptides; 2007 Sep; 28(9):1891-5. PubMed ID: 17582655
[TBL] [Abstract][Full Text] [Related]
4. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury.
Arimura A; Li M; Batuman V
Blood; 2006 Jan; 107(2):661-8. PubMed ID: 16204306
[TBL] [Abstract][Full Text] [Related]
5. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
6. Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases.
Li M; Maderdrut JL; Lertora JJ; Arimura A; Batuman V
Regul Pept; 2008 Jan; 145(1-3):24-32. PubMed ID: 17935800
[TBL] [Abstract][Full Text] [Related]
7. Growth factor-dependent actions of PACAP on oligodendrocyte progenitor proliferation.
Lelievre V; Ghiani CA; Seksenyan A; Gressens P; de Vellis J; Waschek JA
Regul Pept; 2006 Nov; 137(1-2):58-66. PubMed ID: 16989910
[TBL] [Abstract][Full Text] [Related]
8. Changes of dopamine content and cell proliferation by dexamethsone via pituitary adenylate cyclase-activating polypeptide in PC12 cell.
Yang TT; Tsao CW; Li JS; Wu HT; Hsu CT; Cheng JT
Neurosci Lett; 2007 Oct; 426(1):45-8. PubMed ID: 17884294
[TBL] [Abstract][Full Text] [Related]
9. PACAP stimulates the release of interleukin-6 in cultured rat Müller cells.
Seki T; Hinohara Y; Taki C; Nakatani M; Ozawa M; Nishimura S; Takaki A; Itho H; Takenoya F; Shioda S
Ann N Y Acad Sci; 2006 Jul; 1070():535-9. PubMed ID: 16888221
[TBL] [Abstract][Full Text] [Related]
10. Pituitary adenylate cyclase-activating polypeptide stimulates corticotropin-releasing factor, vasopressin and interleukin-6 gene transcription in hypothalamic 4B cells.
Kageyama K; Hanada K; Iwasaki Y; Sakihara S; Nigawara T; Kasckow J; Suda T
J Endocrinol; 2007 Nov; 195(2):199-211. PubMed ID: 17951532
[TBL] [Abstract][Full Text] [Related]
11. Pituitary adenylate cyclase-activating polypeptide stimulates renin secretion via activation of PAC1 receptors.
Hautmann M; Friis UG; Desch M; Todorov V; Castrop H; Segerer F; Otto C; Schütz G; Schweda F
J Am Soc Nephrol; 2007 Apr; 18(4):1150-6. PubMed ID: 17360952
[TBL] [Abstract][Full Text] [Related]
12. Myeloma kidney: toward its prevention--with new insights from in vitro and in vivo models of renal injury.
Sengul S; Li M; Batuman V
J Nephrol; 2009; 22(1):17-28. PubMed ID: 19229815
[TBL] [Abstract][Full Text] [Related]
13. Signaling mechanisms for alpha2-adrenergic inhibition of PACAP-induced growth hormone secretion and gene expression grass carp pituitary cells.
Wang X; Chu MM; Wong AO
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1750-62. PubMed ID: 17311897
[TBL] [Abstract][Full Text] [Related]
14. PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia.
Tang Y; Lv B; Wang H; Xiao X; Zuo X
Int Immunopharmacol; 2008 Dec; 8(12):1646-51. PubMed ID: 18713653
[TBL] [Abstract][Full Text] [Related]
15. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
16. Effects of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide, and somatostatin on the release of thyrotropin from the bullfrog pituitary.
Okada R; Yamamoto K; Ito Y; Chartrel N; Leprince J; Fournier A; Vaudry H; Kikuyama S
Ann N Y Acad Sci; 2006 Jul; 1070():474-80. PubMed ID: 16888212
[TBL] [Abstract][Full Text] [Related]
17. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
[TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic protein down-regulation of neuronal pituitary adenylate cyclase-activating polypeptide and reciprocal effects on vasoactive intestinal peptide expression.
Pavelock KA; Girard BM; Schutz KC; Braas KM; May V
J Neurochem; 2007 Feb; 100(3):603-16. PubMed ID: 17181550
[TBL] [Abstract][Full Text] [Related]
19. Novel stable PACAP analogs with potent activity towards the PAC1 receptor.
Bourgault S; Vaudry D; Botia B; Couvineau A; Laburthe M; Vaudry H; Fournier A
Peptides; 2008 Jun; 29(6):919-32. PubMed ID: 18353507
[TBL] [Abstract][Full Text] [Related]
20. Altered anti-inflammatory response of mononuclear cells to neuropeptide PACAP is associated with deregulation of NF-{kappa}B in chronic pancreatitis.
Michalski CW; Selvaggi F; Bartel M; Mitkus T; Gorbachevski A; Giese T; Sebastiano PD; Giese NA; Friess H
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G50-7. PubMed ID: 17962362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
